Healthcare
QHSLab, Inc.(USAQ)
Live Price
Offline$0.339
-3.14% today
1Y Change
+52.17%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +26.3%
- EPS Growth
- +258.7%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
QHSLab, Inc. (USAQ) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.34 and up 52.2% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +26.3%, EPS growth of +258.7%, a dividend yield of 0.0%. What stands out right now is revenue +26.3%, EPS +258.7%, free cash flow +25.1% with operating margin 4.9% and ROIC 7.5%. Valuation is more restrained than many high-expectation growth names at P/E 15.3 and price/sales 2.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines USAQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+26.3% vs +7.6% peer median
Operating Margin
Below sector median
+4.9% vs +19.4% peer median
P/E
Below sector median
15.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 18, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +26.3% and EPS at +258.7%, with operating margin around 4.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +15.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 18, 2026 | โ | +15.6% | +3.1% | โ |
2026 Mar 30, 2026 | โ | +8.2% | +14.0% | -3.9% |
2025 Nov 13, 2025 | โ | +0.0% | +28.0% | +92.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
USAQ
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
USAQ Max Drawdown
-72.82%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for USAQ and SPY.
Company Overview
QHSLab, Inc.
Other OTC
QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. In addition, the company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. The company was incorporated in 1983 and is based in West Palm Beach, Florida.
- Leadership
- Troy James Grogan
- IPO Date
- May 22, 2013
- Employees
- 4
- Street Address
- 901 Northpoint Parkway
- Mailing
- West Palm Beach, FL, 33407
- Region
- West Palm Beach, FL, US
- Reporting Currency
- USD
- Investor Line
- 929 379 6503
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 15.3
- EV/EBITDA
- 8.1
- Price/Sales
- 2.6
- Price/Book
- 4.3
Growth
- Revenue
- +26.3%
- EPS
- +258.7%
- Free Cash Flow
- +25.1%
Profitability
- Gross Margin
- 67.3%
- Operating Margin
- 4.9%
- Net Margin
- 17.0%
- ROE
- -825.4%
- ROIC
- 7.5%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 1.96
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.